Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77324.260.1507%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Structure Therapeutics Inc

GPCRNASDAQ
Trade with Public
Trade with Public
$38.66
-0.89-2.25%
At close: Sep 11, 5:00 PM EST
$39.65
0.992.56%
After Hours: 7:09 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Structure Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Structure Therapeutics (GPCR).

Price Target Range — 13 Quarters

Analyst Consensus — 16 Analysts

3S.Buy
13Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$98Upside to Avg. PT+147.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026CitizensJonathan WollebenMaintainedMarket Outperform$110
Aug 7, 2026CitigroupSamantha SemenkowPT CutBuy$100→$97
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Structure Therapeutics, Maintains $110 Price Target

Citizens analyst Jonathan Wolleben reiterates Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and maintains $110 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97

Citigroup analyst Samantha Semenkow maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $97.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110

Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.
Benzinga Newsdesk

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Structure Therapeutics, Lowers Price Target to $70

HC Wainwright & Co. analyst Ananda Ghosh maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and lowers the price target from $100 to $70.
Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101

Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved